Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Epidemiology
Published in: European Journal of Epidemiology 5/2010

01-05-2010 | Neuro-Epidemiology

Incidence of Creutzfeldt-Jakob disease in Taiwan: a prospective 10-year surveillance

Authors: Chien-Jung Lu, Yu Sun, Shun-Sheng Chen

Published in: European Journal of Epidemiology | Issue 5/2010

Login to get access

Abstract

This study was performed to estimate the incidence of Creutzfeldt-Jakob Disease (CJD) in Taiwan from 1998 to 2007. Suspected cases of CJD were reported to the Taiwan Creutzfeldt-Jakob Disease Surveillance Unit, a nationwide, hospital-based case report system initiated since 1996 to prospectively conduct a CJD epidemiological study. Consecutive patients who met the diagnostic criteria recommended by the World Health Organization were enrolled. The clinical information of each suspected case was collected and case ascertainment was performed by an expert committee. A total of 123 sporadic CJD were identified without any iatrogenic or new variant CJD cases. The overall annual incidence rate (95% CI) was 0.55 (0.46–0.65) cases per million person-year. There was no statistically significant difference between the calendar year of disease onset (P = 0.97). The incidence rates were not significantly different between women and men (P = 0.63). Age was the main factor for the risk of CJD (P < 0.0001). Age-specific incidence rate increased after the age of 40 years with the peak being in the 70–79 years age group. Our data showed low annual incidence rate and high frequency of methionine homozygous prion protein genotype of sCJD in Taiwan. This report provided important epidemiological data on ethnic Chinese.
Appendix
Available only for authorised users
Literature
1.
Caramelli M, Ru G, Acutis P, Forloni G. Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances. CNS Drugs. 2006;20(1):15–28.CrossRefPubMed
2.
Andrews NJ, Farrington CP, Ward HJ, Cousens SN, Smith PG, Molesworth AM, et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet. 2003;361(9359):751–2.CrossRefPubMed
3.
Capek I, Vaillant V. Creutzfeldt-Jakob disease and related diseases in France from 1998 to 2000. Euro Surveill. 2003;8(1):14–8.PubMed
4.
Collins S, Boyd A, Lee JS, Lewis V, Fletcher A, McLean CA, et al. Creutzfeldt-Jakob disease in Australia 1970–1999. Neurology. 2002;59(9):1365–71.PubMed
5.
D’Aignaux JH, Cousens SN, Delasnerie-Laupretre N, Brandel JP, Salomon D, Laplanche JL, et al. Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998. Int J Epidemiol. 2002;31(2):490–5.CrossRefPubMed
6.
Doi Y, Yokoyama T, Sakai M, Nakamura Y. Creutzfeldt-Jakob disease mortality in Japan, 1979–2004: analysis of national death certificate data. J Epidemiol. 2007;17(4):133–9.CrossRefPubMed
7.
Elsaadany S, Semenciw R, Ricketts M, Mao Y, Giulivi A. Epidemiological study of Creutzfeldt-Jakob disease death certificates in Canada, 1979–2001. Neuroepidemiology. 2005;24(1–2):15–21.CrossRefPubMed
8.
Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 2002;360(9327):139–41.CrossRefPubMed
9.
Heinemann U, Krasnianski A, Meissner B, Varges D, Kallenberg K, Schulz-Schaeffer WJ, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007;130(5):1350–9.CrossRefPubMed
10.
Horan G, Keohane C, Molloy S, Howley R, Harney M, Heffernan J, et al. Creutzfeldt-Jakob disease in Ireland: epidemiological aspects 1980–2002. Eur Neurol. 2004;51(3):132–7.CrossRefPubMed
11.
Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64(9):1586–91.CrossRefPubMed
12.
Puopolo M, Ladogana A, Almonti S, Daude N, Bevivino S, Petraroli R, et al. Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993–2000. J Clin Epidemiol. 2003;56(5):494–9.CrossRefPubMed
13.
Shi Q, Gao C, Zhou W, Zhang BY, Chen JM, Tian C, et al. Surveillance for Creutzfeldt-Jakob disease in China from 2006 to 2007. BMC Public Health. 2008;8:360.CrossRefPubMed
14.
Stratton E, Ricketts MN, Gully PR. The epidemiology of Creutzfeldt-Jakob disease in Canada: a review of mortality data. Emerg Infect Dis. 1997;3(1):63–4.CrossRefPubMed
15.
Van Everbroeck B, Michotte A, Sciot R, Godfraind C, Deprez M, Quoilin S, et al. Increased incidence of sporadic Creutzfeldt-Jakob disease in the age groups between 70 and 90 years in Belgium. Eur J Epidemiol. 2006;21(6):443–7.CrossRefPubMed
16.
Velasquez-Perez L, Rembao-Bojorquez D, Guevara J, Guadarrama-Torres RM, Trejo-Contreras A. Creutzfeldt-Jakob disease in Mexico. Neuropathology. 2007;27(5):419–28.CrossRefPubMed
17.
Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, et al. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993–1995. EU Collaborative Study Group for CJD. Ann Neurol. 1998;43(6):763–7.CrossRefPubMed
18.
Cousens SN, Linsell L, Smith PG, Chandrakumar M, Wilesmith JW, Knight RS, et al. Geographical distribution of variant CJD in the UK (excluding Northern Ireland). Lancet. 1999;353(9146):18–21. (see comment).CrossRefPubMed
19.
20.
Brown P, Cathala F, Raubertas RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology. 1987;37(6):895–904.PubMed
21.
Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, et al. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970–96. BMJ. 1997;315(7105):389–95.PubMed
22.
Satishchandra P, Shankar SK. Creutzfeldt-Jakob disease in India (1971–1990). Neuroepidemiology. 1991;10(1):27–32.CrossRefPubMed
23.
Prusiner SB. Prion biology and diseases. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 2004.
24.
WHO. Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec. 1998;73(47):361–5.
25.
Cambier DM, Kantarci K, Worrell GA, Westmoreland BF, Aksamit AJ. Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. Clin Neurophysiol. 2003;114(9):1724–8.CrossRefPubMed
26.
Tsuji S, Kuroiwa Y. Creutzfeldt-Jakob disease in Japan. Neurology. 1983;33(11):1503–6.PubMed
27.
Will RG, Matthews WB, Smith PG, Hudson C. A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970–1979. II: Epidemiology. J Neurol Neurosurg Psychiatry. 1986;49(7):749–55.CrossRefPubMed
28.
Masullo C, Pocchiari M, Neri G, Casaccia P, Iavarone A, Ladogana A, et al. A retrospective study of Creutzfeldt-Jakob disease in Italy (1972–1986). Eur J Epidemiol. 1988;4(4):482–7.CrossRefPubMed
29.
Radbauer C, Hainfellner JA, Jellinger K, Pilz P, Maier H, Kleinert R, et al. Epidemiology of transmissible spongiform encephalopathies (prion diseases) in Austria. Wien Med Wochenschr. 1998;148(4):101–6.PubMed
30.
Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology. 2000;54(5):1095–9.PubMed
31.
Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5(2):177–88.CrossRefPubMed
32.
Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335(13):924–30.CrossRefPubMed
33.
Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, Terwilliger JD, et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature. 1989;338(6213):342–5.CrossRefPubMed
34.
Salvatore M, Genuardi M, Petraroli R, Masullo C, D’Alessandro M, Pocchiari M. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. Hum Genet. 1994;94(4):375–9.CrossRefPubMed
35.
36.
Finkenstaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology. 1996;199(3):793–8.PubMed
37.
Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996;53(9):913–20.PubMed
38.
Reinwald S, Westner IM, Niedermaier N. Rapidly progressive Alzheimer’s disease mimicking Creutzfeldt-Jakob disease. J Neurol. 2004;251(8):1020–2.CrossRefPubMed
39.
Brown P, Rodgers-Johnson P, Cathala F, Gibbs CJ Jr, Gajdusek DC. Creutzfeldt-Jakob disease of long duration: clinicopathological characteristics, transmissibility, and differential diagnosis. Ann Neurol. 1984;16(3):295–304.CrossRefPubMed
40.
Burns A, O’Brien J, Ames D. Dementia. 3rd ed. London: Hodder Arnold; 2005.
41.
Rabenau HF, Cinatl J, Doerr HW. Prions: a challenge for science, medicine, and public health system. S. Karger; 2004.
42.
Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(2):224–33.CrossRefPubMed
43.
Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994;35(5):513–29.CrossRefPubMed
44.
Zeidler M, Green A. Advances in diagnosing Creutzfeldt-Jakob disease with MRI and CSF 14-3-3 protein analysis. Neurology. 2004;63(3):410–1.PubMed
45.
Cohen CH. Does improvement in case ascertainment explain the increase in sporadic Creutzfeldt-Jakob disease since 1970 in the United Kingdom? Am J Epidemiol. 2000;152(5):474–9.CrossRefPubMed
46.
Dyrbye H, Broholm H, Dziegiel MH, Laursen H. The M129V polymorphism of codon 129 in the prion gene (PRNP) in the Danish population. Eur J Epidemiol. 2008;23(1):23–7.CrossRefPubMed
47.
Nurmi MH, Bishop M, Strain L, Brett F, McGuigan C, Hutchison M, et al. The normal population distribution of PRNP codon 129 polymorphism. Acta Neurol Scand. 2003;108(5):374–8.CrossRefPubMed
48.
Windl O, Dempster M, Estibeiro JP, Lathe R, de Silva R, Esmonde T, et al. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet. 1996;98(3):259–64.CrossRefPubMed
49.
Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352(6333):340–2.CrossRefPubMed
50.
Yu SL, Jin L, Sy MS, Mei FH, Kang SL, Sun GH, et al. Polymorphisms of the PRNP gene in Chinese populations and the identification of a novel insertion mutation. Eur J Hum Genet. 2004;12(10):867–70.CrossRefPubMed
51.
Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39(6):767–78.CrossRefPubMed
52.
Lo RY, Shyu WC, Li H. Long-duration sCJD with PRNP codon 129 methionine homozygosity and cerebral cortical plaques. Neurology. 2006;66(12):1944–5.CrossRefPubMed
53.
Gelpi E, Heinzl H, Hoftberger R, Unterberger U, Strobel T, Voigtlander T, et al. Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study. Neuroepidemiology. 2008;30(4):215–21.CrossRefPubMed
Metadata
Title
Incidence of Creutzfeldt-Jakob disease in Taiwan: a prospective 10-year surveillance
Authors
Chien-Jung Lu
Yu Sun
Shun-Sheng Chen
Publication date
01-05-2010
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 5/2010
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-010-9446-4

Other articles of this Issue 5/2010

European Journal of Epidemiology 5/2010 Go to the issue

Erratum

Erratum to: Ignoring critique, attacking the critic

PERINATAL EPIDEMIOLOGY

Selection by socioeconomic factors into the Danish National Birth Cohort

LOCO-MOTOR DISEASES

Leisure time physical activity in adulthood is positively associated with bone mineral density 22 years later. The Tromsø study

CARDIOVASCULAR DISEASE

Shift-work and cardiovascular disease: a population-based 22-year follow-up study

CARDIOVASCULAR DISEASE

Shift work and risk factors for cardiovascular disease: a study at age 45 years in the 1958 British birth cohort

METHODS

A successful implementation of e-epidemiology: the Danish pregnancy planning study ‘Snart-Gravid’